Enveric Biosciences Inc. (ENVB)
ENVB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2019-12-31, https://www.sec.gov/Archives/edgar/data/890821/000114036120006825/0001140361-20-006825-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2019-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ENVB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000890821 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2019
| Line | Value |
|---|---|
| Revenue | $39.9M |
| Net income | -$2.4M |
| Operating income | -$2.3M |
| Net margin | -6.0% |
| Operating margin | -5.8% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $431K |
| Total assets | $109K |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements." | 10-Q 2026-11-13 |
| Cash and burn | $8.3M cash; operating cash flow -$2.1M a quarter. | Report 2026-06-30 |
| Shares outstanding | 4,475,884 (2026-11-11); 596,978 a year earlier; 2,321,315 three years earlier. 3y figure adjusted for splits (1-for-2700 overall). | Cover page 2026-11-11 |
| Reverse splits, 3 years | 3; latest 1-for-12 on 2025-10-28 | Source 2025-10-28 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-06-09 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., Morristown, New Jersey, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-04-14 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$3.0M | -$2.4M | $8.3M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$1.6M | -$2.3M | $4.9M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$2.2M | -$1.8M | $4.7M | No debt tags | Needs four quarters | 10-K 2026-03-27 |
| Q3 2025 2025-09-30 | Not filed | -$1.9M | -$2.1M | $3.8M | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | Not filed | -$2.5M | -$1.9M | $2.8M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$2.2M | -$2.4M | $4.3M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-12-31 | Not filed | -$3.2M | -$1.3M | $2.2M | No debt tags | Needs four quarters | 10-K 2026-03-27 |
| Q3 2024 2024-09-30 | Not filed | -$2.1M | -$927K | $3.1M | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-09 |
| Latest annual report | 10-K | 2026-03-27 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +6.4% |
| 1 month | +8.2% |
| 3 months | +0.3% |
| Year to date | -58.3% |
| 1 year | -72.3% |
| From 52-week high | -85.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TOVX | Theriva Biologics Inc. | $0.1400 | -2.85% | $6.4M |
| ADXN | Addex Therapeutics Ltd | $3.83 | -5.67% | $6.5M |
| TCRT | Alaunos Therapeutics Inc. | $1.60 | -1.84% | $6.7M |
| SNGX | Soligenix Inc. | $0.2882 | -10.22% | $6.7M |
| FBLG | FibroBiologics Inc. | $0.9034 | -2.00% | $6.1M |
| TPST | Tempest Therapeutics Inc. | $0.3418 | -10.50% | $6.8M |
| XCUR | Exicure Inc. | $1.07 | -0.93% | $7.0M |
| LTRN | Lantern Pharma Inc. | $0.3890 | -10.18% | $5.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier